Dec 23 |
HH-120 for COVID-19: real-time meta analysis of 2 studies | |
| Significantly lower risk is seen for cases and viral clearance. 2 studies (both from the same team) show significant benefit. Meta analysis using the most serious outcome reported shows 49% [-60‑84%] lower risk, without reachin.. | ||
Dec 6 2023 |
et al., Journal of Medical Virology, doi:10.1002/jmv.29275 | Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 prevents SARS‐CoV‐2 infection: Two investigator‐initiated postexposure prophylaxis trials |
| 76% fewer symptomatic cases (p=0.02) and 58% fewer cases (p=0.03). RCT 269 participants showing significantly reduced risk of infection and symptomatic infection with IgM-like ACE2 fusion protein HH-120 nasal spray used as post-exposure prophylaxis. Participants self-administered HH-120 or placebo 5-10 t.. | ||
May 25 2023 |
et al., Journal of Medical Virology, doi:10.1002/jmv.28805 | Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study |
| 20% faster viral clearance (p=0.001). PSM analysis of 65 HH-120 patients and 103 controls contemporaneously hospitalized in the same hospital, showing faster viral clearance with HH-120 treatment, with improved results for patients with higher baseline viral load. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.